We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IDBS and Synthace Announce Strategic Partnership To Streamline Bioprocess Data Management

IDBS and Synthace Announce Strategic Partnership To Streamline Bioprocess Data Management  content piece image
Credit: Ketut Subiyanto/ Pexels
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

IDBS, a global life sciences software company and Synthace, the first life sciences software company to automate biology experimentation and insight sharing in a unified, global R&D environment, have entered into a strategic partnership to provide IDBS Polar™ users with state-of-the-art data foundations for experimentation in high-throughput process development (HTPD). Synthace’s cloud-based automation platform augments Polar’s HTPD capabilities by automating the capture, structuring and enrichment of the millions of data points generated per experiment across disconnected bioreactors and analytical instruments in the bioprocessing laboratory.

Polar HTPD, powered by Synthace, helps bioprocess development teams adopt faster throughput approaches and significantly shorten timelines by supporting better decision making with more reliable data sets, rich data analysis and modern enterprise data management. This combined solution enables users to confidently scale up to hundreds of automated, parallelized experiments per month.

“Speed and improved outcomes are what our customers care about during the development of novel biotherapeutics,” said Christian Marcazzo, Vice President & General Manager, IDBS. “Polar HTPD has been designed to help forward-looking biologics development teams that generate large, highly valuable data to capture, structure, and interpret complex data to make faster and better decisions. Our partnership with Synthace provides faster time-to-value with embedded integrations between laboratory systems and our enterprise cloud platform for biologics R&D.”

Guy Levy-Yurista, PhD, CEO of Synthace, said, “The most innovative bioprocessing organizations are laser-focused on reducing time to Investigational New Drug (IND), while simultaneously improving process robustness and product quality. This is leading many teams to reappraise how they are generating experimental data. We are seeing a fast move towards new automated ways of producing insight-ready data without the need for excessive post-hoc curation steps. Users of our Synthace Life Sciences R&D cloud platform have long been taking advantage of our seamless integration of experimental and data automation to produce insightful data sets enriched with valuable metadata. We’re excited to extend the reach of our unique technology to Polar users through our partnership with leading innovator, IDBS.”